MedMira launches Maple Biosciences division

By Angela McDaniels

Seattle, Jan. 19 - MedMira Inc. said it has launched a new division, Maple Biosciences, to bring to market diagnostic instruments and software components that MedMira predicted will displace enzyme-linked immunoassays, a 30-year-old technology used to conduct routine laboratory tests.

"MedMira is very pleased to embark on this new chapter with the introduction of Maple Biosciences. It will be a new phase of growth for our company which will ensure we remain at the forefront of the diagnostics industry with a product that complements our rapid tests," MedMira chairman and chief executive officer Stephen Sham said in a company news release.

The key benefits of Maple Biosciences' diagnostics instruments are increased lab automation, a high through-put format and digital presentation of results, MedMira said. These features are designed to help deal with shortages of labor and money.

For patients, Maple Biosciences' instruments will enable same-day test results, faster specimen collection and will use a smaller amount of specimen to perform the same tests that currently require multiple vials of blood.

Maple Biosciences' instruments will also diagnose multiple conditions and diseases from a single specimen, the company said.

Based in Halifax, N.S., MedMira manufactures and markets in vitro flow-through rapid diagnostic tests. Maple Biosciences is based in Toronto.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.